[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350592-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350592-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","systemic-immunosuppression-limits-nk-cell-therapy-efficacy-in-pancreatic-cancer","Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer","","Nature killer (NK) cells are central to cancer immunosurveillance and are explored as immunotherapeutic tools for pancreatic ductal adenocarcinoma (PDAC). Systemic immune perturbations are increasingly recognized, yet how PDAC tumor burden reshapes systemic NK cells remains unclear. In PDAC tumor-bearing mice, spleen NKs show reduced frequency and impaired function. Gr-1+ myeloid cells expand and suppress both endogenous and adoptively transferred NK activity, driven by ApoE-mediated lipid metabolism, lipid oxidation, and ROS generation. Targeting ApoE in Gr-1+ myeloid cells or using lipid metabolism inhibitors restores NK effector function in spleen and tumor microenvironments.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/systemic-immunosuppression-limits-nk-cell-therapy-efficacy-in-pancreatic-cancer/350592/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/systemic-immunosuppression-limits-nk-cell-therapy-efficacy-in-pancreatic-cancer/350592.png","ImageObject",300,407,{"name":42,"@type":43},"Well Done","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does PDAC tumor burden affect systemic NK cells in the spleen?","Question",{"text":63,"@type":64},"PDAC tumor-bearing mice show decreased NK cell frequency and dysfunction in the spleen.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role do Gr-1+ myeloid cells play in limiting NK cell therapy efficacy?",{"text":68,"@type":64},"Gr-1+ myeloid cells increase in the spleen and suppress both endogenous and adoptively transferred NK cell frequency and function.",{"name":70,"@type":61,"acceptedAnswer":71},"How does ApoE in Gr-1+ myeloid cells influence NK cell suppression?",{"text":72,"@type":64},"ApoE is upregulated in Gr-1+ myeloid cells, promoting lipid oxidation and reactive oxygen species (ROS) generation that negatively impacts NK cell function.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350592,1790165871,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":104,"preview_page_count":33,"preview_urls":145},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","He etal. Molecular Cancer (2026) 25:170 Molecular Cancer  \n[https://doi.org/10.1186/s12943-025-02340-8](https://doi.org/10.1186/s12943-025-02340-8)  \nRESEARCH Open Access  \nSystemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer  \nChunbo He1†, Dezhen Wang2†, Tuo Hu2, Daisy Gonzalez2, Ravi Thakur1,2, Damian P. Matysniak 1, Ryan J. King2, Sai Sundeep Kollala2, Spas Dimitrov Markov2, Yuki Fujii1, Gullanki Naga Venkata CharanTej1, Junzhang Zhao1, Longyang Jin1, Rebecca Oberley-Deegan3, Surendra K. Shukla 1,11,2, Xin A. Zhang4,11, Jacob E. Friedman5, Pankaj K. Singh 1,11,2, Michael A. Hollingsworth2, Marina Pasca di Magliano6, Howard C. Crawford7,8 and Kamiya Mehla1,9,10,11,2*  \nAbstract  \nNature killer (NK) cell plays a critical role in cancer immunosurveillance and is considered a potent immunotherapeutic tool for many cancers, including pancreatic ductal adenocarcinomas (PDACs) . Increasing evidence suggests that cancer occurs with systemic immune perturbations. However, the effects of PDAC tumor burden on systemic NK cells remain poorly understood. PDAC tumor-bearing mice display decreased frequency and dysfunction of NKs the spleens. We identified an increase in Gr-1+ myeloid cells within the spleens, which negatively impacts both endogenous and adoptively transferred NK cell frequency and function. Apolipoprotein E (ApoE), a lipid metabolism regulator, is upregulated in Gr-1+ myeloid cells of tumor-bearing mice, promoting lipid oxidation and reactive oxygen species (ROS) generation. Genetic knockout of Apoe in Gr-1+ myeloid cells abrogate their suppressive effects on NK cell function. Furthermore, treatment with lipid metabolism inhibitors restores endogenous and adoptively transferred NKs’ effector function in the spleens and tumor microenvironment. These studies underscore the importance of understanding preexisting systemic alterations in PDAC patients before applying NK cell-based immunotherapies.  \nKeywords Pancreatic ductal adenocarcinomas (PDAC), Apolipoprotein E (ApoE), Lipid oxidation, Lipid peroxidation, NK cells, Myeloid-derived suppressive cells (MDSCs), Immunotherapies  \n†Chunbo He and Dezhen Wang contributed equally to this work.  \n*Correspondence:  \nKamiya Mehla  \n[kamiya-mehla@ouhsc.edu](kamiya-mehla@ouhsc.edu)  \n1Department of Oncology Science, University of Oklahoma Health Campus, 940 Stanton L. Young Blvd., BMSB 332, Oklahoma City, OK 73104, USA  \n2Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA  \n3Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA  \n4Department of Biochemistry and Physiology, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA  \n5Harold Hamm Diabetes Center, University of Oklahoma Health Campus, Oklahoma City, OK 73117, USA  \n6Department of Surgery, University of Michigan, Ann Arbor, MI, USA 7Department of Pharmacology and Toxicology, Michigan State University, Lansing, MI, USA  \n8Department of Surgery, Henry Ford Health System, Detroit, MI, USA 9Department of Microbiology and Immunology, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA  \n10Department of Pathology, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA  \n11OU Health Stephenson Cancer Center, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third par","cbCaia8hwtfEp8pD","https://ap.wps.com/l/cbCaia8hwtfEp8pD","pdf",14304883,"English","# Abstract\n# Background","[{\"question\":\"How does PDAC tumor burden affect systemic NK cells in the spleen?\",\"answer\":\"PDAC tumor-bearing mice show decreased NK cell frequency and dysfunction in the spleen.\"},{\"question\":\"What role do Gr-1+ myeloid cells play in limiting NK cell therapy efficacy?\",\"answer\":\"Gr-1+ myeloid cells increase in the spleen and suppress both endogenous and adoptively transferred NK cell frequency and function.\"},{\"question\":\"How does ApoE in Gr-1+ myeloid cells influence NK cell suppression?\",\"answer\":\"ApoE is upregulated in Gr-1+ myeloid cells, promoting lipid oxidation and reactive oxygen species (ROS) generation that negatively impacts NK cell function.\"}]","Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer | PDF",1790089776,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56c7b150879f41758f1c22cff52208c8.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db67b4cc93165d6b9ae8515f72e47004.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/099aa47789a2e1ee631b09d0c4616086.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6da9352c4ba652b9c0284b63484c5f7.webp",980,1306]